Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus oxaliplatin versus S-1 alone in elderly patients with advanced gastric cancer
jRCTs041190004Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing S-1 monotherapy with S-1 + oxaliplatin (2 arms). Primary endpoint: overall survival. Started May 2016; status: active, not recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs041190004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190004.